Hugues Lecat Appointed to Guerbet Board, Nominated for Chairman Role
Guerbet, a specialist in contrast agents and medical imaging solutions, has appointed Hugues Lecat as a "Censeur" (director without voting rights) with the intention of him becoming chairman.
Villepinte, France, March 20, 2024 – Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced the appointment of Hugues Lecat as a "Censeur" (a non-voting board director) with immediate effect. The appointment is subject to approval by shareholders at the upcoming General Meeting.
Following the shareholder meeting, Lecat is slated to be nominated as Chairman of the Board of Directors, succeeding Didier Izabel. Izabel will continue to serve as a director and Chairman of the Audit Committee until the end of his term in 2026. Lecat brings extensive experience from leadership roles within the pharmaceutical sector.
"We are delighted that Hugues Lecat has agreed to join the Guerbet Group," stated Eric Guerbet, representing the Guerbet family shareholders. "His management experience in large pharmaceutical companies will help guide the Group towards further success. His understanding of governance issues and strategic vision will be valuable assets."
Lecat expressed enthusiasm for the opportunity, saying, "I am thrilled to join the Board of Directors and to have the opportunity to subsequently take over as its Chairman. I look forward to contributing to the Group's future success and supporting CEO David Hale in developing strategies to strengthen our market position."
Lecat's career includes significant roles at companies such as Medtronic, Aventis Pharma, Sanofi-Aventis OTC, Cooper Consumer Health, and Ethypharm, where he served as Chairman and CEO. His appointment is expected to bolster Guerbet's standing in the diagnostic and interventional imaging markets globally.